Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells

Basic Research in Cardiology

Volumn 94, Issue 5, 1999, Pages 322-332

  Riessen, R ^a   Axel, D I ^a   Fenchel, M ^a   Herzog, U U ^a   Rossmann H ^a   Karsch, K R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Atherosclerosis; Extracellular matrix; HMG CoA reductase inhibitors; Smooth muscle; Thrombospondin

Indexed keywords

BIGLYCAN; COLLAGEN TYPE 1; FIBRONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SCLEROPROTEIN; SIMVASTATIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

CELL DIVISION; CELLS, CULTURED; COLLAGEN; DNA; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ILIAC ARTERY; LOVASTATIN; MUSCLE, SMOOTH, VASCULAR; PRAVASTATIN; SIMVASTATIN; THROMBOSPONDINS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032880948     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003950050158     Document Type: Article

References (57)

1. Amento EP, Ehsani N, Palmer H, Libby P (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11: 1223-1230
2. Axel DI, Brehm BR, Wolburg-Buchholz K, Betz EL, Köveker G, Karsch KR (1996) Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells. J Vasc Res 33: 327-339
3. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96: 636-645
4. Bauters C, Marotte F, Hamon M, Oliviero P, Farhadian F, Robert V, Samuel JL, Rappaport L (1995) Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries. Circulation 92: 904-911
5. Bernard MP, Kolbe M, Weil D, Chu ML (1985) Human cellular fibronectin: comparison of the carboxyl-terminal portion with rat identifies primary structural domains separated by hypervariable regions. Biochemistry 2698-2704
6. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hephill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, MARS Research Group (1993) Coronary angiographic changes with lovastatin therapy. Ann Intern Med 119: 969-976
7. Bocan TMA, Mazur MJ, Bak Mueller S, Quenby Brown E, Sliskovic DR, O'Brien PM, Creswell MW, Lee H, Uhlendorf PD, Roth BD, Newton RS (1994) Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme. A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 11: 127-142
8. ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323-8327
9. Chojnacki T, Dallner G (1988) The biological role of dolichol. Biochem J 251: 1-9
10. Chu ML, Myers JC, Bernard MP, Ding JF, Ramirez F (1982) Cloning and characterization of five overlapping cDNAs specific for the human proα1(I) collagen chain. Nucl Ac Res 10: 5925-5934
11. Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, Adelman AG, Rabinovitch M (1995) Expression of tumour necrosis factor a and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 73: 534-539
12. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101: 117-126
13. Derynck R, Jarret JA, Chen EY, Eaton DH, Bell J, Assoian RK, Roberts AB, Sporn MB, Goeddel DV (1985) Human transforming growth factor-β cDNA sequence and expression in tumor cell lines. Nature 316: 701-705
14. Dey NB, Boerth NJ, MurphyUllrich JE, Chang PL, Prince CW, Lincoln TM (1998) Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res 82: 139-146
15. 32P-based hybridizations. Anal Biochem 210: 235-244
16. Fisher LW, Termine JD, Young MF (1989) Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 264: 4571-4576
17. Glomset JA, Gelb JE, Farnsworth CC (1992) Geranylgeranylated proteins. Biochem Soc Trans 20: 479-484
18. Goldstein JL, Brown MS (1990) Regulation of mevalonate pathway. Nature 343: 425-430
19. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD (1998) Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 97: 946-952
20. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Egido J (1998) 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490-500
21. Guo NH, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57: 1735-1742
22. Hengst L, Reed SI (1996) Translational control of p27kipl accumulation during the cell cycle. Science 271: 1861-1864
23. Iruela-Arispe ML, Bornstein P, Sage H (1991) Thrombospondin excerts an anti-angiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 88: 5026-5030
24. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z (1991) Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632
25. Lawler J, Hynes RO (1986) The structure of human thrombospondin: an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 103: 1635-1648
26. MAAS Investigators (1994) Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344: 633-638
27. Majack RA, Goodman LV, Dixit VM (1988) Cell surface thrombospondin is functionally essential for vascular smooth muscle proliferation. J Cell Biol 106: 415-422
28. Majack RA, Majesky MW, Goodman LV (1990) Role of PDGF-A expression in the control of vascular smooth muscle cell growth by transforming growth factor-β. J Cell Biol 111: 239-247
29. Massy ZA, Keane WF, Kasiske BL (1996) Inhibition of mevalonate pathway: benefits beyond cholesterol reduction? Lancet 347: 102-103
30. Mayne R (1986) Collageneous proteins of blood vessels. Arteriosclerosis 6: 585-593
31. McDonald JA, Broekelmann TJ, Matheke ML, Crouch E, Koo M, Kuhn C (1986) A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. J Clin Invest 78: 1237-1244
32. Miano JM, Vlasic N, Tota RR, Stemerman MB (1993) Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth. Arteriosclerosis Thromb 13: 211-219
33. Munro E, Patel M, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P (1994) Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24: 766-772
34. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GCF, van Leeuwen REW, Cohen LH (1997) Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other cell types. Biochim Biophys Acta 1345: 259-268
35. Nikkari ST, Jarvelainen HT, Wight TN, Ferguson M, Clowes AW (1994) Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol 144: 1348-1356
36. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA (1990) Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30: 1128-1135
37. Patel MK, Lymn JS, Clunn GF, Hughes AD (1997) Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 2107-2114
38. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Hagfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453-1460
39. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD (1992) Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans, J Clin Pharmacol 32: 136-142
40. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker G, Braunwald E (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98: 839-844
41. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN (1994) Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 144: 962-974
42. Riessen R, Kearney M, Lawler J, Isner JM (1998) Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J 135: 357-364
43. Riessen R, Wight TN, Pastore C, Henley C, Isner JM (1996) Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 93: 1141-1147
44. Rogler G, Lackner KJ, Schmitz G (1995) Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro. Basic Res Cardiol 90: 443-450
45. Sacks FM, Pfeffer MA, Moye LA, Rouleau Jl, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009
46. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
47. Schönherr E, Järveläinen HT, Kinsella MG, Sandell LJ, Wight TN (1993) Platelet derived growth factor and transforming growth factor-β1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arteriosclerosis Thromb 13: 1026-1036
48. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE (1995) Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 270: 7304-7310
49. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307
50. Silverstein RL, Harpel PC, Nachman RL (1986) Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. J Biol Chem 261: 9959-9965
51. Silverstein RL, Leung LL, Harpel PC, Nachman RL (1984) Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J Clin Invest 74: 1625-1633
52. Sindermann J, Weigel K, Muller JG, Breithardt G (1996) Lovastatin causes downregulation of cyclin-dependent kinase 2, upregulation of tyrosine phosphorylation, and is capable of inducing apoptosis in human, bovine and rat vascular smooth muscle cells. Circulation 94 (Suppl. I): I-638 (Abstract)
53. Sindermann J, Weigel K, Müller JG, Schmidt A, Breithardt G (1997) Induction of p53 and interleukin-8 by hydroxy methyl coenzyme A reductase inhibitors in human coronary smooth muscle cells. Eur Heart J 18: Abstr. Suppl 371 (Abstract)
54. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW (1995) A definition of advanced types of atherosclerotic lesions and a histologic classification of atherosclerosis. Circulation 92: 1355-1374
55. West of Scotland Coronary Prevention Study Group (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97: 1440-1445
56. Yabkowitz R, Mansfield PJ, Ryan US, Suchard SJ (1993) Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol 157: 24-32
57. Yasugi E, Yokoyama Y, Seyama Y, Kano K, Hayashi Y, Oshima M (1995) Dolichyl phosphate, a potent inducer of apoptosis in rat glioma C6 cells. Biochem Biophys Res Com 216: 848-853